Isentress Approval Expanded to Include Children and Teens

To combat AIDS-causing virus

WEDNESDAY, Dec. 21 (HealthDay News) -- Approval for the HIV drug Isentress (raltegravir) has been expanded to include children and adolescents ages 2-18, the U.S. Food and Drug Administration said Wednesday.

The drug is an integrase strand transfer inhibitor that helps slow the spread of the AIDS-causing virus throughout the body, the agency said in a news release. It was first approved for adults in October 2007.

The twice-daily pill is available in a chewable form for people aged 2 to 11, and in non-chewable form. Clinical testing of the drug among 96 children and teens with HIV-1 infection showed 53 percent of patients had undetectable blood HIV levels after 24 weeks, the FDA said.

The most common reported side effects of Isentress included trouble sleeping and headache.

The drug does not cure HIV infection, and patients must take Isentress continually to ensure ongoing reduction in HIV-related illness, the FDA stressed.

The drug is produced by Merck & Co., based in Whitehouse Station, N.J.

More information

The U.S. Department of Health and Human Services has more about HIV/AIDS.

Scott Roberts

Related Articles

Learn More About Sharp
Sharp HealthCare is San Diego's health care leader with seven hospitals, two medical groups and a health plan. Learn more about our San Diego hospitals, choose a Sharp-affiliated San Diego doctor or browse our comprehensive medical services.

Health News is provided as a service to Sharp Web site users by HealthDay. Sharp HealthCare nor its employees, agents, or contractors, review, control, or take responsibility for the content of these articles. Please read the Terms of Use for more information.